|Number of samples:||18|
|Release date:||Aug 25 2015|
|Last update date:||Oct 10 2018|
|Chemicals:||Antidepressive Agents, Tricyclic, Desipramine|
|Dataset link||RGS9-2-controlled adaptations in the striatum determine the onset of action and eficacy of antidepressants in neuropathic pain states|
The RNAseq study was designed in order to reveal the impact of RGS9-2 on gene regulation in the Nucleus Accumbens under neuropathic pain and antidepressant treatment conditions. A total of 18 samples was used, coprising 6 different groups , and each group consisted of three different biological replicates.